# US 2024/0254513 A1 · Viral vector production systems, engineered cells for viral vector production, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254513 A1
- Document ID: US20240254513A1
- Status: Published application
- Kind: A1
- Application number: 18/561,050
- Filed: 2022-05-17
- Published: 2024-08-01
- Earliest claimed: 2021-05-18
- Assignees: Asimov Inc.
- Applicants: Asimov Inc.
- Inventors: Jeremy J. Gam; Christopher S. Stach; Alec A.K. Nielsen
- Web page: https://patentgrep.com/patent/US20240254513A1

## CPC

- C12N 15/86: Viral vectors
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2750/14043: viral genome or elements thereof as genetic vector
- C12N 2750/14052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2800/40: Systems of functionally co-operating vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are viral vector production systems and engineered cells for viral vector production. Also described herein are methods of using the engineered cells to produce viral vectors.

## Claims

### Claim 1

A viral vector production system comprising:
(a) an engineered cell comprising a viral vector production component comprising one or more heterologous polynucleic acids that collectively encode the gene products of a viral vector;
(b) a heterologous nucleic acid sequence encoding for a first expression cassette, wherein the first expression cassette comprises a nucleic acid sequence of a constitutive promoter operably linked to a nucleic acid sequence encoding a regulatory RNA; and
(c) a transfer polynucleic acid comprising a central nucleic acid sequence flanked, on the 5′ and 3′ end, by a nucleic acid sequence of a viral terminal repeat.

### Claim 2 (depends on 1)

The viral vector production system of claim 1, wherein the central nucleic acid sequence of the transfer polynucleic acid comprises a nucleic acid sequence encoding a multiple cloning site.

### Claim 3 (depends on 2)

The viral vector production system of claim 2, wherein the central nucleic acid sequence comprises a multiple cloning sequence flanked by a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette.

### Claim 4 (depends on 3)

The viral vector production system of claim 3, wherein the multiple cloning sequence is flanked by a tandem repeat of a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette.

### Claim 5 (depends on 3, 4)

The viral vector production system of claim 3 or claim 4, wherein the multiple cloning sequence is flanked on the 5′ end and the 3′ end by a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette.

### Claim 6 (depends on 2, 3, 4, 5)

The viral vector production system of any one of claims 2-5, wherein the central nucleic acid sequence further comprises a promoter.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The viral vector production system of any one of claims 1-6, wherein the central nucleic acid sequence of the transfer polynucleic acid sequence comprises a second expression cassette, wherein the second expression cassette comprises a nucleic acid sequence encoding a payload molecule operably linked to both a promoter and a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette.

### Claim 8 (depends on 7)

The viral vector production system of claim 7, wherein the nucleic acid sequence of the payload molecule comprises: a 5′ UTR that comprises a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette; a 3′ UTR that comprises a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette; or a combination thereof.

### Claim 9 (depends on 7, 8)

The viral vector production system of claim 7 or claim 8, wherein the nucleic acid sequence of the payload molecule comprises a tandem repeat of a target nucleic acid sequence that complements the regulatory RNA encoded by the first expression cassette.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The viral vector production system of any one of claims 1-9, wherein the first expression cassette comprises a tandem repeat of the nucleic acid sequence encoding the regulatory RNA.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The viral vector production system of any one of claims 1-10, wherein the first expression cassette comprises a nucleic acid sequence of two or more distinct regulatory RNAs.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The viral vector production system of any one of claims 1-11, wherein the first expression cassette further comprises a nucleic acid sequence encoding a gene product of the viral vector production component.

### Claim 13 (depends on 12)

The viral vector production system of claim 12, wherein the nucleic acid sequence encoding the gene product in the first expression cassette has: a 5′ UTR comprising the nucleic acid sequence encoding the regulatory RNA; an intron comprising the nucleic acid sequence encoding the regulatory RNA; a 3′ UTR comprising the nucleic acid sequence encoding the regulatory RNA; or a combination thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The viral vector production system of any one of claims 1-13, wherein the first expression cassette further comprises a nucleic acid sequence encoding a selectable marker.

### Claim 15 (depends on 14)

The viral vector production system of claim 14, wherein the selectable marker comprises a fluorescent protein or antibiotic resistance protein.

### Claim 16 (depends on 14, 15)

The viral vector production system of claim 14 or claim 15, wherein the nucleic acid sequence encoding the selectable maker in the first expression cassette has a 5′ UTR comprising the nucleic acid sequence encoding the regulatory RNA; an intron comprising the nucleic acid sequence encoding the regulatory RNA; a 3′ UTR comprising the nucleic acid sequence encoding the regulatory RNA; or a combination thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The viral vector production system of any one of claims 1-16, wherein the viral vector production system is an AAV viral vector production system, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of an AAV vector.

### Claim 18 (depends on 17)

The viral vector production system of claim 17, wherein the viral vector component comprises the nucleic acid sequences of Rep52 or Rep40; Rep78 or Rep68; E2A; E4Orf6; VARNA; VP1; VP2; VP3; and AAP.

### Claim 19 (depends on 17, 18)

The viral vector production system of claim 17 or claim 18, wherein the viral terminal repeats of the transfer polynucleic acid are AAV inverted tandem repeats.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The viral vector production system of any one of claims 1-16, wherein the viral vector production system is a lentivirus vector production system, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of a lentivirus vector.

### Claim 21 (depends on 20)

The viral vector production system of claim 20, wherein the viral vector component comprises the nucleic acid sequences of VSV-G, Gag-Pol, and Rev.

### Claim 22 (depends on 20, 21)

The viral vector production system of claim 20 or claim 21, wherein the viral terminal repeats of the transfer polynucleic acid are lentivirus long terminal repeats.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The viral vector production system of any one of claims 1-22, wherein at least one of the one or more of heterologous polynucleic acids of the viral vector production component is stably integrated into the genome of the engineered cell.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The viral vector production system of any one of claims 1-23, wherein each of the one or more of heterologous polynucleic acids of the viral vector production component is stably integrated into the genome of the engineered cell.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The viral vector production system of any one of claims 1-24, wherein the engineered cell further comprises the heterologous nucleic acid sequence encoding for the first expression cassette.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The viral vector production system of any one of claims 1-25, wherein the engineered cell is derived from a HEK293 cell, a HeLa cell, a BHK cell or a Sf9 cell.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The viral vector production system of any one of claims 1-26, wherein the regulatory RNA is an shRNA or an amiRNA.

### Claim 28 (depends on 27)

The viral vector production system of claim 27, wherein the nucleic acid sequence encoding the shRNA comprises a nucleic acid sequence of any one of SEQ ID NOs: 2-11.

### Claim 29 (depends on 27, 28)

The viral vector production system of claim 27 or claim 28, wherein the first expression cassette comprises a nucleic acid sequence encoding for a selectable marker, wherein the nucleic acid sequence encoding for the selectable marker comprises an intron having, from 5′ to 3′: (i) an intron donor site; (ii) a nucleic acid sequence encoding for the shRNA or amiRNA; and (iii) an intron acceptor site.

### Claim 30 (depends on 29)

The viral vector production system of claim 29, wherein the intron comprises a tandem repeat, an shRNA cluster, or an amiRNA cluster of the nucleic acid sequence encoding for the shRNA or amiRNA.

### Claim 31 (depends on 29, 30)

The viral vector production system of claim 29 or claim 30, wherein the nucleic acid sequence encoding for the selectable marker comprises: a 5′ UTR, wherein the intron of the selectable marker is located in the 5′ UTR; a 3′UTR, and wherein the intron of the selectable marker is located in the 3′ UTR; or a combination thereof.

### Claim 32 (depends on 29, 30, 31)

The viral vector production system of any one of claims 29-31, wherein the intron of the selectable marker is located in the coding region of the nucleic acid sequence encoding for the selectable marker.

### Claim 33 (depends on 28, 29, 30, 31)

The viral vector production system of any one of claims 28-31, wherein the intron comprises the nucleic acid sequence of SEQ ID NO: 12.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The viral vector production system of any one of claims 1-26, wherein the regulatory RNA is a Cas13 guide RNA.

### Claim 35 (depends on 34)

The viral vector production system of claim 34, wherein the first expression cassette comprises a constitutive promoter operably linked to a nucleic acid sequence encoding two or more Cas13 guide RNAs.

### Claim 36 (depends on 34, 35)

The viral vector production system of claim 34 or claim 35, further comprising a heterologous polynucleic acid encoding for Cas13.

### Claim 37 (depends on 36)

The viral vector production system of claim 36, wherein the Cas13 is Cas13d.

### Claim 38 (depends on 37)

The viral vector production system of claim 37, wherein Cas13d comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 39 (depends on 36, 37, 38)

The viral vector production system of any one of claims 36-38, wherein heterologous polynucleic acid encoding for Cas13 further comprises the first expression cassette.

### Claim 40 (depends on 39)

The viral vector production system of claim 39, wherein the first expression cassette comprises a nucleic acid sequence of a constitutive promoter operably linked to both the nucleic acid sequence encoding the Cas13 gRNA and the nucleic acid sequence encoding for Cas13.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The viral vector production system of any one of claims 36-40, wherein the engineered cell further comprises the heterologous polynucleic acid encoding for Cas13.

### Claim 42

An engineered cell for viral vector production comprising one or more heterologous polynucleic acids collectively comprising:
(a) a viral vector production component collectively encoding the gene products of a viral vector;
(b) a first expression cassette, wherein the first expression cassette comprises a nucleic acid sequence of a constitutive promoter operably linked to a nucleic acid sequence encoding an shRNA or amiRNA; and
(c) a transfer polynucleic acid comprising a central nucleic acid sequence flanked, on the 5′ and 3′ end, by a nucleic acid sequence of a viral terminal repeat, wherein the central nucleic acid sequence comprises a nucleic acid sequence encoding a payload molecule operably linked to both a promoter and a target nucleic acid sequence that complements the shRNA or amiRNA encoded by the first expression cassette.

### Claim 43 (depends on 42)

The engineered cell of claim 42, wherein the nucleic acid sequence of the payload molecule comprises: a 5′ UTR that comprises a target nucleic acid sequence that complements the shRNA or amiRNA encoded by the first expression cassette; a 3′ UTR that comprises a target nucleic acid sequence that complements the shRNA or amiRNA encoded by the first expression cassette; or a combination thereof.

### Claim 44 (depends on 42, 43)

The engineered cell of claim 42 or claim 43, wherein the nucleic acid sequence of the payload molecule comprises a tandem repeat of a target nucleic acid sequence that complements the shRNA or amiRNA encoded by the first expression cassette.

### Claim 45 (depends on 42, 43, 44)

The engineered cell of any one of claims 42-44, wherein the first expression cassette comprises a tandem repeat, shRNA cluster or amiRNA cluster of the nucleic acid sequence encoding the shRNA or amiRNA.

### Claim 46 (depends on 42, 43, 44, 45)

The engineered cell of any one of claims 42-45, wherein the first expression cassette comprises a nucleic acid sequence of two or more distinct shRNAs or two or more distinct amiRNAs.

### Claim 47 (depends on 42, 43, 44, 45)

The engineered viral vector production system of any one of claims 42-45, wherein the first expression cassette comprises a nucleic acid sequence encoding for a selectable marker, wherein the nucleic acid sequence encoding for the selectable marker comprises an intron having, from 5′ to 3′: (i) an intron donor site; (ii) a nucleic acid sequence encoding for the shRNA or amiRNA; and (iii) an intron acceptor site.

### Claim 48 (depends on 47)

The engineered cell of claim 47, wherein the intron comprises a tandem repeat shRNA cluster or amiRNA cluster of the nucleic acid sequence encoding for the shRNA or amiRNA.

### Claim 49 (depends on 47, 48)

The engineered cell of claim 47 or claim 48, wherein nucleic acid sequence encoding for the selectable marker comprises: a 5′ UTR, wherein the intron of the selectable marker is located in the 5′ UTR; a 3′UTR, wherein the intron of the selectable marker is located in the 3′ UTR; or a combination thereof.

### Claim 50 (depends on 47, 48, 49)

The engineered cell of any one of claims 47-49, wherein the intron of the selectable marker is located in the coding region of the nucleic acid sequence encoding for the selectable marker.

### Claim 51 (depends on 47, 48, 49, 50)

The engineered cell of any one of claims 47-50, wherein the intron comprises the nucleic acid sequence of SEQ ID NO: 12.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The engineered cell of any one of claims 42-50, wherein the nucleic acid sequence encoding the shRNA comprises the nucleic acid sequence of any of SEQ ID NOs: 2-11.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The engineered cell of any one of claims 42-52, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of an AAV vector.

### Claim 54 (depends on 53)

The engineered cell of claim 53, wherein the viral vector component comprises the nucleic acid sequences of Rep52 or Rep40; Rep78 or Rep68; E2A; E4Orf6; VARNA; VP1; VP2; VP3; and AAP.

### Claim 55 (depends on 54)

The engineered cell of 53 or claim 54, wherein the viral terminal repeats of the transfer polynucleic acid are AAV inverted tandem repeats.

### Claim 56 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The engineered cell of any one of claims 42-52, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of a lentivirus vector.

### Claim 57 (depends on 56)

The engineered cell of claim 56, wherein the viral vector component comprises the nucleic acid sequences of VSV-G, Gag-Pol, and Rev.

### Claim 58 (depends on 56, 57)

The engineered cell of claim 56 or claim 57, wherein the viral terminal repeats of the transfer polynucleic acid are lentivirus long terminal repeats.

### Claim 59 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The engineered cell of any one of claims 42-58, wherein at least one of the one or more of heterologous polynucleic acids is stably integrated into the genome of the engineered cell.

### Claim 60 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The engineered cell of any one of claims 42-59, wherein each of the one or more of heterologous polynucleic acids are stably integrated into the genome of the engineered cell.

### Claim 61 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The engineered cell of any one of claims 42-60, wherein the engineered cell is derived from a HEK293 cell a HeLa cell, a BHK cell or a Sf9 Cell.

### Claim 62 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A method of reducing expression of a payload molecule during viral vector production in the engineered cell any one of claims 42-60, comprising expressing the shRNA or amiRNA during viral vector production.

### Claim 63

An engineered cell for viral vector production comprising one or more heterologous polynucleic acids collectively comprising:
(a) a viral vector production component collectively encoding the gene products of a viral vector;
(b) a first expression cassette, wherein the first expression cassette comprises a nucleic acid sequence of a constitutive promoter operably linked to a nucleic acid sequence encoding a Cas13 guide RNA;
(c) a nucleic acid sequence encoding Cas13; and
(d) a transfer polynucleic acid comprising a central nucleic acid sequence flanked, on the 5′ and 3′ end, by a nucleic acid sequence of a viral terminal repeat, wherein the central nucleic acid sequence comprises a nucleic acid sequence encoding a payload molecule operably linked to both a promoter and a target nucleic acid sequence that complements the Cas13 guide RNA encoded by the first expression cassette.

### Claim 64 (depends on 63)

The engineered cell of claim 63, wherein the first expression cassette comprises a constitutive promoter operably linked to a nucleic acid sequence encoding two or more Cas13 guide RNAs.

### Claim 65 (depends on 63, 64)

The engineered cell of claim 63 or claim 64, wherein the Cas13 is Cas13d.

### Claim 66 (depends on 65)

The engineered cell of claim 65, wherein Cas13d comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 1.

### Claim 67 (depends on 63, 64, 65)

The engineered cell of any one of claims 63-65, wherein the first expression cassette further comprises the nucleic acid sequence encoding for Cas13.

### Claim 68 (depends on 67)

The engineered cell of claim 67, wherein the first expression cassette comprises a nucleic acid sequence of a constitutive promoter operably linked to both the nucleic acid sequence encoding the Cas13 gRNA and the nucleic acid sequence encoding for Cas13.

### Claim 69 (depends on 63, 64, 65, 66, 67, 68)

The engineered cell of any one of claims 63-68, wherein the nucleic acid sequence of the payload molecule comprises: a 5′ UTR that comprises a target nucleic acid sequence that complements the Cas13 guide RNA encoded by the first expression cassette; a 3′ UTR that comprises a target nucleic acid sequence that complements the Cas13 guide RNA encoded by the first expression cassette; or a combination thereof.

### Claim 70 (depends on 63, 64, 65, 66, 67, 68, 69)

The engineered cell of any one of claims 63-69, wherein the nucleic acid sequence of the payload molecule comprises a tandem repeat of a target nucleic acid sequence that complements the Cas13 guide RNA encoded by the first expression cassette.

### Claim 71 (depends on 63, 64, 65, 66, 67, 68, 69, 70)

The engineered cell of any one of claims 63-70, wherein the first expression cassette comprises a tandem repeat of the nucleic acid sequence encoding the Cas13 guide RNA.

### Claim 72 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71)

The engineered cell of any one of claims 63-71, wherein the first expression cassette comprises a nucleic acid sequence of two or more distinct Cas13 guide RNAs.

### Claim 73 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The engineered cell of any one of claims 63-72, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of an AAV vector.

### Claim 74 (depends on 73)

The engineered cell of claim 73, wherein the viral vector component comprises the nucleic acid sequences of Rep52 or Rep40; Rep78 or Rep68; E2A; E4Orf6; VARNA; VP1; VP2; VP3; and AAP.

### Claim 75 (depends on 74)

The engineered cell of 73 or claim 74, wherein the viral terminal repeats of the transfer polynucleic acid are AAV inverted tandem repeats.

### Claim 76 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The engineered cell of any one of claims 63-72, wherein the viral vector production component comprises one or more polynucleic acids that collectively encode the gene products of a lentivirus vector.

### Claim 77 (depends on 76)

The engineered cell of claim 76, wherein the viral vector component comprises the nucleic acid sequences of VSV-G, Gag-Pol, and Rev.

### Claim 78 (depends on 76, 77)

The engineered cell of claim 76 or claim 77, wherein the viral terminal repeats of the transfer polynucleic acid are lentivirus long terminal repeats.

### Claim 79 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The engineered cell of any one of claims 63-78, wherein at least one of the one or more of heterologous polynucleic acids is stably integrated into the genome of the engineered cell.

### Claim 80 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The engineered cell of any one of claims 63-79, wherein each of the one or more of heterologous polynucleic acids are stably integrated into the genome of the engineered cell.

### Claim 81 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The engineered cell of any one of claims 63-80, wherein the engineered cell is derived from a HEK293 cell, a HeLa cell, a BHK cell or a Sf9 Cell.

### Claim 82 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method of reducing expression of a payload molecule during viral vector production in the engineered cell any one of claims 63-81, comprising expressing the Cas13 and the Cas13 guide RNA during viral vector production.
